4.7 Article

IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms

期刊

BLOOD
卷 140, 期 26, 页码 2805-2817

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022017326.

关键词

-

资金

  1. National Institutes of Health(NIH)
  2. National Cancer Institute (NCI) [R35CA253096]
  3. MPN Research Consortium [P01CA108671]
  4. NIH
  5. NCI [R01CA265009]
  6. Samuel WaxmanCancer Research Foundation
  7. St. Jude/American Lebanese SyrianAssociated Charities

向作者/读者索取更多资源

This study analyzed MF mouse models and samples from MF patients, and found that high levels of IL-13 are associated with MF progression and fibrosis. Inhibition of the IL-13/IL-4 signaling pathway may serve as a novel therapeutic target for treating MF.
Myelofibrosis (MF) is a disease associated with high unmet medical needs because allo-geneic stem cell transplantation is not an option for most patients, and JAK inhibitors are generally effective for only 2 to 3 years and do not delay disease progression. MF is characterized by dysplastic megakaryocytic hyperplasia and progression to fulminant disease, which is associated with progressively increasing marrow fibrosis. Despite evi-dence that the inflammatory milieu in MF contributes to disease progression, the specific factors that promote megakaryocyte growth are poorly understood. Here, we analyzed changes in the cytokine profiles of MF mouse models before and after the development of fibrosis, coupled with the analysis of bone marrow populations using single-cell RNA sequencing. We found high interleukin 13 (IL-13) levels in the bone marrow of MF mice. IL-13 promoted the growth of mutant megakaryocytes and induced surface expression of transforming growth factor beta and collagen biosynthesis. Similarly, analysis of samples from patients with MF revealed elevated levels of IL-13 in the plasma and increased IL-13 receptor expression in marrow megakaryocytes. In vivo, IL-13 overexpression promoted disease progression, whereas reducing IL-13/IL-4 signaling reduced several features of the disease, including fibrosis. Finally, we observed an increase in the number of marrow T cells and mast cells, which are known sources of IL-13. Together, our data demonstrate that IL-13 is involved in disease progression in MF and that inhibition of the IL-13/IL-4 signaling pathway might serve as a novel therapeutic target to treat MF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据